ArticleRSC advances2025
Lumbrokinase-loaded GelMA hydrogels with inflammatory regulatory capacity promote vascularized bone regeneration in critical-sized cranial defects.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Injectable hydrogels for bone regeneration: from materials design to clinical translation.RSC advances · 2026Review
- Article
- Functionalized GelMA-based hydrogels for osteoimmunomodulation and bone regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Size-Optimized LDH Nanoplatelet-Reinforced GelMA Hydrogels Orchestrate Osteoimmunomodulation for Critical-Sized Bone Defect Repair.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of critical-sized bone defects resulting from trauma and resective surgeries still poses significant clinical challenges. Factors contributing to inadequate bone regeneration in critical-sized defects are complex and multifaceted, including vascular injury and inflammation. Inspired by earthworms' remarkable regenerative abilities, we incorporated lumbrokinase (LK), an extract from earthworms, into injectable gelatin methacryloyl (GelMA) hydrogels to achieve controlled release of LK, thereby enhancing vascularized bone regeneration in critical-sized defects. While LK has been clinically utilized as an antithrombotic agent for decades in treating cerebrovascular and cardiovascular diseases, this study reveals its novel anti-inflammatory properties and dual capacity to promote both osteogenesis and angiogenesis. The LK-loaded GelMA hydrogel demonstrated favorable biocompatibility, good injectability and viscoelastic properties, tunable degradation kinetics, and optimal swelling characteristics. Comprehensive
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.